The Clorox Company

NYSE:CLX

Household & Personal Products

Consumer Defensive
$108.39 -2.60%

-$2.54 today

Market cap
$13.13B
Beta
0.55
P/E (TTM)
15.2
EPS (TTM)
$6.23
Dividend yield
5.22%
52W Low $84.70High $132.03

Volume 2.16M

Average 2.84M

CLX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

The Clorox CompanyNYSE: CLX

Research & Development · Q1 FY2027 · quarter ended Sep 2026

Research & development growth accelerates

Q1 FY2027 research & development of $29M rose 3.6% year over year, ahead of the -0.8% change in trailing-twelve-month research & development. Sequentially, it fell 9.4% from the prior quarter. Over 3 fiscal years it compounded at -5.6% a year.

Context

  • Research & development amounted to 1.7% of revenue in FY2026, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2026 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +3.6% holds above the trailing-twelve-month pace of -0.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$29M-9.4% QoQ
Last fiscal yearJun 2026
$116M-4.1% YoY
LTMSep 2026
$117M-0.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.6%——
1 year-4.1%——
3-year CAGR-5.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2026
116M USD
Year-over-year change
-4.1%
4-year CAGR
-3.2%

Research & Development vs competitors

How CLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.8% is the 2nd highest of 6, against a peer median of -100.0%.
  • Research & development amounts to 1.6% of revenue for CLX, versus a peer median of 0.0%.
CLX Competitors
Research & Development for CLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KVUEKenvue Inc.LTM Sep 2026$180M USD——1.2%
CLXThe Clorox CompanyLTM Sep 2026$117M USD-0.8%-5.6%1.6%
EPCEdgewell Personal Care CompanyLTM Mar 2026$58.5M USD-0.3%+1.2%2.8%
SPBSpectrum Brands Holdings, Inc.LTM Jun 2026$10.7M USD-59.8%—0.4%
PGThe Procter & Gamble CompanyLTM Sep 2026$0 USD——0.0%
ULUnilever PLCFY2025€0 EUR——0.0%
CLColgate-Palmolive CompanyLTM Sep 2026$0 USD-100.0%+4.6%0.0%
KMBKimberly-Clark CorporationLTM Jun 2026$0 USD-100.0%—0.0%
CHDChurch & Dwight Co., Inc.LTM Sep 2026$0 USD——0.0%
REYNReynolds Consumer Products Inc.LTM Jun 2026$0 USD——0.0%
HELEHelen of Troy LimitedLTM Feb 2026$0 USD-100.0%+4.1%0.0%
Peer median (excluding CLX) —-100.0%+4.1%0.0%

Competitors are the stored peer set for CLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue7.11B7.39B7.09B7.1B6.72B
Cost of Revenue4.56B4.48B4.05B3.89B3.88B
Gross Profit2.55B2.91B3.05B3.21B2.84B
Gross Margin35.8%39.4%43.0%45.2%42.3%
Research & Development132M138M126M121M116M
Selling, General & Admin1.66B1.92B2.17B1.89B1.07B
Operating Expenses1.83B2.09B2.33B2.04B1.18B
Depreciation & Amortization224M236M235M219M247M
EBITDA937M564M723M1.39B1.17B
EBITDA Margin13.2%7.6%10.2%19.5%17.4%
Operating Income719M823M723M1.18B1.66B
Operating Margin10.1%11.1%10.2%16.6%24.7%
Interest Income5M16M23M9M8M
Interest Expense106M90M90M88M130M
Other Income / Expenses(112M)(585M)(325M)(99M)(871M)
Income Before Tax607M238M398M1.08B791M
Pre-Tax Margin8.5%3.2%5.6%15.2%11.8%
Income Tax Expense136M77M106M254M190M
Net Income462M149M280M810M587M
Net Margin6.5%2.0%3.9%11.4%8.7%
EPS (Basic)3.751.212.256.564.82
EPS (Diluted)3.731.202.256.524.81
Weighted Avg Shares123.11M123.59M124.17M123.53M121.78M
Weighted Avg Shares (Diluted)123.91M124.18M124.8M124.29M122.13M

The Clorox Company

NYSE:CLX

Intrinsic Alpha fair value

Locked

Current Price

$108.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.